{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:40:05Z","timestamp":1793047205189,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MR1-2022-12376594"],"award-info":[{"award-number":["PNRR-MR1-2022-12376594"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ricerca Corrente 5x1000 from Childrens\u2019 Hospital Bambino Ges\u00f9, Rome, Italy","award":["202205_INFETT_CIFALDI"],"award-info":[{"award-number":["202205_INFETT_CIFALDI"]}]},{"name":"Ricerca Corrente 5x1000 from Childrens\u2019 Hospital Bambino Ges\u00f9, Rome, Italy","award":["202205_INFETT_CIFALDI"],"award-info":[{"award-number":["202205_INFETT_CIFALDI"]}]},{"name":"Development of Innovative Diagnostic and Therapeutic Approaches for PID grant","award":["Programma di rete, NET- 2011-02350069"],"award-info":[{"award-number":["Programma di rete, NET- 2011-02350069"]}]},{"name":"Development of Innovative Diagnostic and Therapeutic Approaches for PID grant","award":["Programma di rete, NET- 2011-02350069"],"award-info":[{"award-number":["Programma di rete, NET- 2011-02350069"]}]},{"name":"Pharming Group N.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10875-024-01835-1","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T04:08:50Z","timestamp":1734926930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase \u03b4 Syndrome\u00a0in the Target Therapy Era"],"prefix":"10.1007","volume":"45","author":[{"given":"Federica","family":"Barzaghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Moratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Rivalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Giardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Augusta","family":"Baselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Chinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marzollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Montin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Marinoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Costagliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldassarre","family":"Martire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Trizzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Badolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cancrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Lougaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"issue":"3","key":"1835_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","volume":"59","author":"M Jamee","year":"2020","unstructured":"Jamee M, Moniri S, Zaki-Dizaji M, et al. Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review. Clin Rev Allergy Immunol. 2020;59(3):323\u201333. https:\/\/doi.org\/10.1007\/s12016-019-08738-9.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6160","key":"1835_CR2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Gar\u00e7on F, et al. Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866\u201371. https:\/\/doi.org\/10.1126\/science.1243292.","journal-title":"Science"},{"issue":"4","key":"1835_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605\u201335. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029.","journal-title":"Cell"},{"issue":"1","key":"1835_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","volume":"15","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating, germline mutations in phosphoinositide 3-Kinase p110\u03b4 cause T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88\u201397. https:\/\/doi.org\/10.1038\/ni.2771.","journal-title":"Nat Immunol"},{"issue":"6","key":"1835_CR5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221020","volume":"220","author":"T Nguyen","year":"2023","unstructured":"Nguyen T, Lau A, Bier J, et al. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3K\u03b4 syndrome 2. J Exp Med. 2023;220(6): e20221020. https:\/\/doi.org\/10.1084\/jem.20221020.","journal-title":"J Exp Med"},{"key":"1835_CR6","doi-asserted-by":"publisher","unstructured":"Maccari ME, Abolhassani H, Aghamohammadi A, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-Kinase \u03b4 syndrome: the European society for immunodeficiencies-activated phosphoinositide 3-Kinase \u03b4 syndrome registry. Front Immunol. 2018;9. https:\/\/doi.org\/10.3389\/fimmu.2018.00543.","DOI":"10.3389\/fimmu.2018.00543"},{"key":"1835_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1279652","volume":"14","author":"S Vanselow","year":"2023","unstructured":"Vanselow S, Hanitsch L, Hauck F, et al. Future directions in the diagnosis and treatment of APDS and IEI: a survey of German IEI centers. Front Immunol. 2023;14: 1279652. https:\/\/doi.org\/10.3389\/fimmu.2023.1279652.","journal-title":"Front Immunol"},{"issue":"1","key":"1835_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaip.2023.09.016","volume":"12","author":"AJ Cant","year":"2024","unstructured":"Cant AJ, Chandra A, Munro E, Rao VK, Lucas CL. PI3K\u03b4 pathway dysregulation and unique features of its inhibition by Leniolisib in activated PI3K\u03b4 syndrome and beyond. J Allergy Clin Immunol Pract. 2024;12(1):69\u201378. https:\/\/doi.org\/10.1016\/j.jaip.2023.09.016.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"1835_CR9","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.4049\/jimmunol.2000326","volume":"205","author":"N Diaz","year":"2020","unstructured":"Diaz N, Juarez M, Cancrini C, et al. Seletalisib for activated PI3K\u03b4 syndromes: open-label phase 1b and extension studies. J Immunol Baltim Md 1950. 2020;205(11):2979\u201387. https:\/\/doi.org\/10.4049\/jimmunol.2000326.","journal-title":"J Immunol Baltim Md 1950"},{"key":"1835_CR10","doi-asserted-by":"publisher","unstructured":"Gunerka P, Gala K, Banach M, et al. Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of asthma. PLoS ONE. 2020;15(7). https:\/\/doi.org\/10.1371\/journal.pone.0236159.","DOI":"10.1371\/journal.pone.0236159"},{"key":"1835_CR11","doi-asserted-by":"publisher","unstructured":"Khindri S, Cahn A, Begg M, et al. A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma. J Pharmacol Exp Ther. 2018;367(3):405\u201313. https:\/\/doi.org\/10.1124\/jpet.118.249516.","DOI":"10.1124\/jpet.118.249516"},{"issue":"5","key":"1835_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/d41573-023-00061-5","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. FDA approves PI3K inhibitor for a rare immune disorder. Nat Rev Drug Discov. 2023;22(5):342\u2013342. https:\/\/doi.org\/10.1038\/d41573-023-00061-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1835_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2023.06.015","volume":"152","author":"ME Maccari","year":"2023","unstructured":"Maccari ME, Wolkewitz M, Schwab C, et al. Activated phosphoinositide 3-kinase \u03b4 syndrome: update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol. 2023;152(4):984-e99610. https:\/\/doi.org\/10.1016\/j.jaci.2023.06.015.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1835_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103335","volume":"9","author":"G Tessarin","year":"2020","unstructured":"Tessarin G, Rossi S, Baronio M, et al. Activated phosphoinositide 3-Kinase delta syndrome 1: clinical and immunological data from an Italian cohort of patients. J Clin Med. 2020;9(10): 3335. https:\/\/doi.org\/10.3390\/jcm9103335.","journal-title":"J Clin Med"},{"issue":"4","key":"1835_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10875-022-01218-4","volume":"42","author":"L Qiu","year":"2022","unstructured":"Qiu L, Wang Y, Tang W, et al. Activated phosphoinositide 3-Kinase \u03b4 syndrome: a large pediatric cohort from a single center in China. J Clin Immunol. 2022;42(4):837\u201350. https:\/\/doi.org\/10.1007\/s10875-022-01218-4.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1835_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","volume":"139","author":"TI Coulter","year":"2017","unstructured":"Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597-e6064. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.021.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1835_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","volume":"138","author":"E Elkaim","year":"2016","unstructured":"Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase \u03b4 syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210-e2189. https:\/\/doi.org\/10.1016\/j.jaci.2016.03.022.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1835_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/08820139.2020.1863982","volume":"51","author":"S Fekrvand","year":"2022","unstructured":"Fekrvand S, Delavari S, Chavoshzadeh Z, et al. The first Iranian cohort of pediatric patients with activated phosphoinositide 3-Kinase-\u03b4 (PI3K\u03b4) syndrome (APDS). Immunol Invest. 2022;51(3):644\u201359. https:\/\/doi.org\/10.1080\/08820139.2020.1863982.","journal-title":"Immunol Invest"},{"issue":"11","key":"1835_CR19","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1016\/j.jaip.2021.07.044","volume":"9","author":"J Oh","year":"2021","unstructured":"Oh J, Garabedian E, Fuleihan R, Cunningham-Rundles C. Clinical manifestations and outcomes of activated phosphoinositide 3-Kinase \u03b4 syndrome from the USIDNET cohort. J Allergy Clin Immunol Pract. 2021;9(11):4095\u2013102. https:\/\/doi.org\/10.1016\/j.jaip.2021.07.044.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"1835_CR20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s10875-018-0568-x","volume":"38","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wang W, Liu L, et al. Report of a Chinese cohort with activated phosphoinositide 3-Kinase \u03b4 syndrome. J Clin Immunol. 2018;38(8):854\u201363. https:\/\/doi.org\/10.1007\/s10875-018-0568-x.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1835_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.aller.2019.12.006","volume":"48","author":"AA Ahmed","year":"2020","unstructured":"Ahmed AA, El Shahaway AA, Hussien SA. Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency. Allergol Immunopathol (Madr). 2020;48(6):686\u201393. https:\/\/doi.org\/10.1016\/j.aller.2019.12.006.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"2","key":"1835_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cei.12706","volume":"183","author":"M Elgizouli","year":"2016","unstructured":"Elgizouli M, Lowe DM, Speckmann C, et al. Activating PI3K\u03b4 mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol. 2016;183(2):221\u20139. https:\/\/doi.org\/10.1111\/cei.12706.","journal-title":"Clin Exp Immunol"},{"key":"1835_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.imlet.2017.08.021","volume":"190","author":"F Saettini","year":"2017","unstructured":"Saettini F, Pelagatti MA, Sala D, et al. Early diagnosis of PI3K\u03b4 syndrome in a 2 years old girl with recurrent otitis and enlarged spleen. Immunol Lett. 2017;190:279\u201381. https:\/\/doi.org\/10.1016\/j.imlet.2017.08.021.","journal-title":"Immunol Lett"},{"key":"1835_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.703056","volume":"9","author":"A Marzollo","year":"2021","unstructured":"Marzollo A, Bresolin S, Colavito D, et al. Case report: intestinal nodular lymphoid hyperplasia as first manifestation of activated PI3K\u03b4 syndrome due to a novel PIK3CD variant. Front Pediatr. 2021;9: 703056. https:\/\/doi.org\/10.3389\/fped.2021.703056.","journal-title":"Front Pediatr"},{"key":"1835_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.703853","volume":"9","author":"B Rivalta","year":"2021","unstructured":"Rivalta B, Amodio D, Milito C, et al. Case report: EBV chronic infection and lymphoproliferation in four APDS patients: the challenge of proper characterization, therapy, and follow-up. Front Pediatr. 2021;9: 703853. https:\/\/doi.org\/10.3389\/fped.2021.703853.","journal-title":"Front Pediatr"},{"issue":"6","key":"1835_CR26","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.jaip.2018.02.029","volume":"6","author":"E Valencic","year":"2018","unstructured":"Valencic E, Grasso AG, Conversano E, et al. Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiency. J Allergy Clin Immunol Pract. 2018;6(6):2165\u20137. https:\/\/doi.org\/10.1016\/j.jaip.2018.02.029.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1835_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clim.2015.12.008","volume":"178","author":"M Chiriaco","year":"2017","unstructured":"Chiriaco M, Brigida I, Ariganello P, et al. The case of an APDS patient: defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. Clin Immunol Orlando Fla. 2017;178:20\u20138. https:\/\/doi.org\/10.1016\/j.clim.2015.12.008.","journal-title":"Clin Immunol Orlando Fla"},{"issue":"7","key":"1835_CR28","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/j.jaip.2021.04.017","volume":"9","author":"C Milito","year":"2021","unstructured":"Milito C, Lougaris V, Giardino G, et al. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. J Allergy Clin Immunol Pract. 2021;9(7):2904-e29062. https:\/\/doi.org\/10.1016\/j.jaip.2021.04.017.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"1835_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13833","volume":"33","author":"F Conti","year":"2022","unstructured":"Conti F, Pacillo L, Amodio D, et al. SARS-CoV-2 infection and treatment in a cohort of patients with inborn errors of immunity. Pediatr Allergy Immunol off Publ Eur Soc Pediatr Allergy Immunol. 2022;33(8): e13833. https:\/\/doi.org\/10.1111\/pai.13833.","journal-title":"Pediatr Allergy Immunol off Publ Eur Soc Pediatr Allergy Immunol"},{"key":"1835_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891274","volume":"13","author":"B Rivalta","year":"2022","unstructured":"Rivalta B, Amodio D, Giancotta C, et al. Case report: successful treatment with monoclonal antibodies in one APDS patient with prolonged SARS-CoV-2 infection not responsive to previous lines of treatment. Front Immunol. 2022;13: 891274. https:\/\/doi.org\/10.3389\/fimmu.2022.891274.","journal-title":"Front Immunol"},{"key":"1835_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.702546","volume":"9","author":"F Conti","year":"2021","unstructured":"Conti F, Catelli A, Cifaldi C, et al. Case report: Hodgkin lymphoma and refractory systemic lupus erythematosus unveil activated phosphoinositide 3-Kinase-\u03b4 syndrome 2 in an adult patient. Front Pediatr. 2021;9: 702546. https:\/\/doi.org\/10.3389\/fped.2021.702546.","journal-title":"Front Pediatr"},{"issue":"9","key":"1835_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao VK, Webster S, \u0160ediv\u00e1 A, et al. A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood. 2023;141(9):971\u201383. https:\/\/doi.org\/10.1182\/blood.2022018546.","journal-title":"Blood"},{"key":"1835_CR33","doi-asserted-by":"publisher","unstructured":"Marc E, Rothenberg MD, PhD J, Bousquet MD. News beyond our pages. J Allergy Clinical Immunol. 2016; 138(1):1\u20132https:\/\/doi.org\/10.1016\/j.jaci.2016.05.013.","DOI":"10.1016\/j.jaci.2016.05.013."},{"issue":"21","key":"1835_CR34","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","volume":"130","author":"VK Rao","year":"2017","unstructured":"Rao VK, Webster S, Dalm VASH, et al. Effective activated PI3K\u03b4 syndrome-targeted therapy with the PI3K\u03b4 inhibitor leniolisib. Blood. 2017;130(21):2307\u201316. https:\/\/doi.org\/10.1182\/blood-2017-08-801191.","journal-title":"Blood"},{"issue":"2","key":"1835_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/ni.2796","volume":"15","author":"PK Chattopadhyay","year":"2014","unstructured":"Chattopadhyay PK, Gierahn TM, Roederer M, Love JC. Single-cell technologies for monitoring immune systems. Nat Immunol. 2014;15(2):128\u201335. https:\/\/doi.org\/10.1038\/ni.2796.","journal-title":"Nat Immunol"},{"issue":"1","key":"1835_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","volume":"153","author":"VK Rao","year":"2024","unstructured":"Rao VK, Kulm E, \u0160ediv\u00e1 A, et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J Allergy Clin Immunol. 2024;153(1):265-e2749. https:\/\/doi.org\/10.1016\/j.jaci.2023.09.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"1835_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143525","volume":"20","author":"JS Jeong","year":"2019","unstructured":"Jeong JS, Kim JS, Kim SR, Lee YC. Defining bronchial asthma with phosphoinositide 3-Kinase delta activation: towards endotype-driven management. Int J Mol Sci. 2019;20(14): 3525. https:\/\/doi.org\/10.3390\/ijms20143525.","journal-title":"Int J Mol Sci"},{"key":"1835_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.02005","volume":"8","author":"JM Carpier","year":"2017","unstructured":"Carpier JM, Lucas CL. Epstein-barr virus susceptibility in activated PI3K\u03b4 syndrome (APDS) immunodeficiency. Front Immunol. 2017;8: 2005. https:\/\/doi.org\/10.3389\/fimmu.2017.02005.","journal-title":"Front Immunol"},{"key":"1835_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2018.00237","volume":"9","author":"JI Cohen","year":"2018","unstructured":"Cohen JI. Herpesviruses in the activated phosphatidylinositol-3-Kinase-\u03b4 syndrome. Front Immunol. 2018;9:9. https:\/\/doi.org\/10.3389\/fimmu.2018.00237.","journal-title":"Front Immunol."},{"issue":"2","key":"1835_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/10428194.2019.1672056","volume":"61","author":"M Herber","year":"2020","unstructured":"Herber M, Mertz P, Dieudonn\u00e9 Y, et al. Primary immunodeficiencies and lymphoma: a systematic review of literature. Leuk Lymphoma. 2020;61(2):274\u201384. https:\/\/doi.org\/10.1080\/10428194.2019.1672056.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"1835_CR41","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/gut.52.10.1472","volume":"52","author":"H Sheng","year":"2003","unstructured":"Sheng H, Shao J, Townsend CM, Evers BM. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut. 2003;52(10):1472\u20138. https:\/\/doi.org\/10.1136\/gut.52.10.1472.","journal-title":"Gut"},{"key":"1835_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118513","volume":"262","author":"S Fattahi","year":"2020","unstructured":"Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH, Akhavan-Niaki H. PI3K\/AKT\/mTOR signaling in gastric cancer: epigenetics and beyond. Life Sci. 2020;262: 118513. https:\/\/doi.org\/10.1016\/j.lfs.2020.118513.","journal-title":"Life Sci"},{"issue":"3","key":"1835_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031848","volume":"25","author":"DT Morgos","year":"2024","unstructured":"Morgos DT, Stefani C, Miricescu D, et al. Targeting PI3K\/AKT\/mTOR and MAPK signaling pathways in gastric cancer. Int J Mol Sci. 2024;25(3): 1848. https:\/\/doi.org\/10.3390\/ijms25031848.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1835_CR44","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1634\/theoncologist.2019-0514","volume":"24","author":"T Komiya","year":"2019","unstructured":"Komiya T, Blumenthal GM, DeChowdhury R, et al. A pilot study of sirolimus in subjects with Cowden syndrome or other syndromes characterized by germline mutations in PTEN. Oncologist. 2019;24(12):1510-e1265. https:\/\/doi.org\/10.1634\/theoncologist.2019-0514.","journal-title":"Oncologist"},{"issue":"1","key":"1835_CR45","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","volume":"149","author":"D Dimitrova","year":"2022","unstructured":"Dimitrova D, Nademi Z, Maccari ME, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022;149(1):410-e4217. https:\/\/doi.org\/10.1016\/j.jaci.2021.04.036.","journal-title":"J Allergy Clin Immunol"},{"key":"1835_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clim.2017.03.004","volume":"179","author":"M Bravo Garc\u00eda-Morato","year":"2017","unstructured":"Bravo Garc\u00eda-Morato M, Garc\u00eda-Mi\u00f1a\u00far S, Molina Garicano J, et al. Mutations in PIK3R1 can lead to APDS2, SHORT syndrome or a combination of the two. Clin Immunol Orlando Fla. 2017;179:77\u201380. https:\/\/doi.org\/10.1016\/j.clim.2017.03.004.","journal-title":"Clin Immunol Orlando Fla"},{"key":"1835_CR47","doi-asserted-by":"publisher","unstructured":"Moreno-Corona N, Chentout L, Poggi L, et al. Two monogenetic disorders, activated PI3-Kinase-\u03b4 syndrome 2 and Smith\u2013Magenis syndrome, in one patient: case report and a literature review of neurodevelopmental impact in primary immunodeficiencies associated with disturbed PI3K signaling. Front Pediatr. 2021;9. https:\/\/doi.org\/10.3389\/fped.2021.688022.","DOI":"10.3389\/fped.2021.688022"},{"issue":"12","key":"1835_CR48","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.3390\/ijms19123725","volume":"19","author":"K S\u00e1nchez-Alegr\u00eda","year":"2018","unstructured":"S\u00e1nchez-Alegr\u00eda K, Flores-Le\u00f3n M, Avila-Mu\u00f1oz E, Rodr\u00edguez-Corona N, Arias C. PI3K signaling in neurons: a Central Node for the control of multiple functions. Int J Mol Sci. 2018;19(12):3725. https:\/\/doi.org\/10.3390\/ijms19123725.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1835_CR49","doi-asserted-by":"publisher","first-page":"e869","DOI":"10.1371\/journal.pone.0000869","volume":"2","author":"BJ Eickholt","year":"2007","unstructured":"Eickholt BJ, Ahmed AI, Davies M, et al. Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase. PLoS ONE. 2007;2(9):e869. https:\/\/doi.org\/10.1371\/journal.pone.0000869.","journal-title":"PLoS ONE"},{"issue":"1","key":"1835_CR50","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12974-021-02325-6","volume":"18","author":"E Chu","year":"2021","unstructured":"Chu E, Mychasiuk R, Hibbs ML, Semple BD. Dysregulated phosphoinositide 3-kinase signaling in microglia: shaping chronic neuroinflammation. J Neuroinflammation. 2021;18(1):276. https:\/\/doi.org\/10.1186\/s12974-021-02325-6.","journal-title":"J Neuroinflammation"},{"issue":"30","key":"1835_CR51","doi-asserted-by":"publisher","first-page":"12165","DOI":"10.1073\/pnas.1206118109","volume":"109","author":"AJ Law","year":"2012","unstructured":"Law AJ, Wang Y, Sei Y, et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110\u03b4 inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A. 2012;109(30):12165\u201370. https:\/\/doi.org\/10.1073\/pnas.1206118109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1835_CR52","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/jmedgenet-2014-102803","volume":"52","author":"L Spinelli","year":"2015","unstructured":"Spinelli L, Black FM, Berg JN, Eickholt BJ, Leslie NR. Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes. J Med Genet. 2015;52(2):128\u201334. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102803.","journal-title":"J Med Genet"},{"key":"1835_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2023.102201","volume":"79","author":"M Begg","year":"2023","unstructured":"Begg M, Amour A, Jarvis E, et al. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of activated PI3 kinase delta syndrome. Pulm Pharmacol Ther. 2023;79: 102201. https:\/\/doi.org\/10.1016\/j.pupt.2023.102201.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"1835_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10238-023-01259-y","volume":"24","author":"J Hanson","year":"2024","unstructured":"Hanson J, Bonnen PE. Systematic review of mortality and survival rates for APDS. Clin Exp Med. 2024;24(1):17. https:\/\/doi.org\/10.1007\/s10238-023-01259-y.","journal-title":"Clin Exp Med"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01835-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-024-01835-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01835-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:45:24Z","timestamp":1777304724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-024-01835-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1835"],"URL":"https:\/\/doi.org\/10.1007\/s10875-024-01835-1","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in strict adherence to the Helsinki Declaration: participants or their parents provided written informed consent for the collection and publication of any data included in this article, which was approved by the local ethical committee of each centre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Authors V.L., C.C., F.C., A.To., A.Tr., R.B., M.Z., F.B., C.P. received an honorarium from Pharming Group N.V. to participate in the APDS advisory board. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"58"}}